Adamas Pharmaceuticals, Inc Earning Date (ADMS)

USA |NASDAQ |USD

ADMS Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 8, 2022 Jun 2022 - - $-0.27
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 8, 2022 Jun 2022 - - $21.97M

Adamas Pharmaceuticals, Inc's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.

ADMS Earnings Date & History Chart

ADMS Earnings & Revenue Forecast

ADMS Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $-0.37 $-0.75 $0.41

ADMS Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-0.36 $-0.36 $-0.36

ADMS Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $127.11M $105.00M $150.10M

ADMS Earnings Date & Revenue History

ADMS Earnings History

|
Show More
Show More

ADMS Revenue History

|
Show More
Show More

Adamas Pharmaceuticals, Inc Next Earnings Date & Report

ADMS Next Earnings Date & Report Preview: Jun 2022 (FQ)

ADMS's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.

Adamas Pharmaceuticals, Inc Previous Earnings Dates & Reports

ADMS Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Adamas Pharmaceuticals, Inc's previous earnings date was May 9, 2022 for its fiscal quarter ended Mar 31, 2022.

ADMS Previous Earnings Date & Report Recap: Dec 2020 (FY)

Adamas Pharmaceuticals, Inc's previous annual earnings date was Feb 23, 2021 for its fiscal year ended Dec 31, 2020.

ADMS's earnings per share (EPS) was $-2.02, missing the consensus analysts forecast of $-1.91 by 5.76% , and higher than the previous year's EPS (Dec 2019) by -46.84%.

Revenues were $74.46M, better than the forecast of $74.39M by 0.10%, and up by 36.28% from previous year's revenue.

The company reported a net income of $-57.40M.

Adamas Pharmaceuticals, Inc reported a free cash flow of $-50.71M for its fiscal year, compared to $-80.80M a year ago.

The company ended the fiscal year with $129.96M in total debt, an increase of 1.76% compared to the previous year.